


What is claimed is:

1. A compound according to formula (I) hereinbelow:

(I) herein below:



( I )

- 5  $R_1$  represents  $\text{CONH}_2$ ;  
 $R_2$  represents  $\text{NR}_4\text{R}_5$ ;  
 $R_3$  is selected from the group consisting of H, CN,  $\text{CF}_3$ , halogen, aryl, heteroaryl, alkyl, O-alkyl, and S-alkyl; and can be attached to either  $C_4$ ,  $C_5$ ,  $C_6$  or  $C_7$ ;  
 $R_4$  represents H or alkyl; and
- 10  $R_5$  is selected from the group consisting of H, CO-alkyl,  $\text{SO}_2$ -alkyl,  $\text{CONH}_2$ , CONH-alkyl, CONH-aryl, CONH-heteroaryl,  $\text{CSNH}_2$ ,  $\text{CSNH}$ -alkyl,  $\text{CSNH}$ -aryl,  $\text{CSNH}$ -heteroaryl,  $\text{SO}_2\text{NH}_2$ ,  $\text{SO}_2\text{NH}$ -alkyl,  $\text{SO}_2\text{NH}$ -aryl, and  $\text{SO}_2\text{NH}$ -heteroaryl; or a pharmaceutically acceptable salt thereof.
- 15 2. A compound according to claim 1 wherein the compound is selected from the group consisting of:  
 2-Amino-6-(4-fluoro-phenyl)-benzo[b]thiophene-3-carboxylic acid amide; and  
 2-Ureido-benzo[b]thiophene-3-carboxylic acid amide.
- 20 3. A method of treating a disease characterized by pathological NF- $\kappa\text{B}$  activation comprising inhibiting the pathological activation by administering to a patient in need thereof an effective amount of a compound according to claim 1.
4. A method according to claim 3 wherein the disease is an inflammatory or  
 25 tissue repair disorder.
5. A method according to Claim 4 wherein the disease is selected from the group consisting of inflammatory and tissue repair disorders, particularly rheumatoid

- arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage, autoimmune diseases including systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiectasia.
6. A method according to Claim 3 wherein said disease is dermatosis.
7. A method according to Claim 3 wherein the disease is selected from the group consisting of: psoriasis, atopic dermatitis, and UV-induced skin damage.
8. A method according to Claim 3 wherein the disease is selected from the group consisting of autoimmune diseases; tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, osteoarthritis, osteoporosis, and Ataxia Telangiectasia.
9. A method according to Claim 3 wherein said disease is an autoimmune disease.
10. A method according to Claim 4 wherein the autoimmune disease is systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, or ankylosing spondylitis, diabetes
11. A method according to any one of Claim 1 wherein the disease is cancer and or cachexia.
12. A method according to Claim 3 wherein the cancer is Hodgkins disease.

13. A method according to Claim 3 wherein the disease is inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS).
- 5 14. A method according to Claim 3 wherein the disease is AIDS.
15. A method according to Claim 3 wherein the disease is adult respiratory distress syndrome.
17. A method according to claim 4 wherein there is dual inhibition of NF- $\kappa$ B and  
10 checkpoint kinase.